Aromatase Inhibitors

Publication Title: 
Cancer Nursing

BACKGROUND: Aromatase inhibitors (AIs) have been established as successful adjuvant therapy for breast cancer survivors. Unfortunately, nearly half of women taking AIs report joint pain, AI-associated arthralgia (AIA). Aromatase inhibitor-associated arthralgia often results in noncompliance, which could lead to cancer recurrence. OBJECTIVE: The purpose of this study was to identify current pain management of AIA and to evaluate the study quality and effects of interventions.

Author(s): 
Yang, Gee Su
Kim, Hee Jun
Griffith, Kathleen A.
Zhu, Shijun
Dorsey, Susan G.
Renn, Cynthia L.
Publication Title: 
Critical Reviews in Oncology/Hematology

Aromatase Inhibitors (AI) are widely used for the adjuvant treatment of hormone receptor positive breast cancers in the post-menopausal population. AI are often associated with significant joint and muscular symptoms; symptoms that are commonly referred to as aromatase inhibitor-associated musculoskeletal syndrome (AIMSS). AIMSS adversely impacts health-related quality of life of many patients, and reduces AI compliance.

Author(s): 
Roberts, Kate
Rickett, Kirsty
Greer, Ristan
Woodward, Natasha
Publication Title: 
Integrative Cancer Therapies

BACKGROUND: Aromatase inhibitors (AIs) are commonly used as adjunctive hormone treatment for early breast cancer patients. The major side effect of AIs is arthralgia, which affects adherence. Previous reviews suggested that acupuncture is effective in the management of cancer-related pain. The aim of this review is to evaluate the effects of acupuncture on arthralgia caused by AIs. METHODS: This article examined randomized controlled trials (RCTs) measuring the effects of acupuncture on joint symptoms caused by AIs within 8 medical databases till May 2014.

Author(s): 
Bae, Kyeore
Yoo, Hwa-Seung
Lamoury, Gillian
Boyle, Frances
Rosenthal, David S.
Oh, Byeongsang
Publication Title: 
Journal of Alternative and Complementary Medicine (New York, N.Y.)

PURPOSE: Acupuncture has been used as a complementary medical treatment for arthralgia and other types of pain. The objective of this review is to assess the effectiveness of acupuncture in the treatment of arthralgia in patients with breast cancer who were treated with aromatase inhibitors (AIs). METHODS: A literature search was performed, without language restrictions, of 10 databases from their inception through February 2014.

Author(s): 
Chien, Tsai-Ju
Liu, Chia-Yu
Chang, Yi-Fang
Fang, Ching-Ju
Hsu, Chung-Hua
Publication Title: 
Human Reproduction Update

BACKGROUND: Here we describe the consensus guideline methodology, summarise the evidence-based recommendations we provided to the World Health Organisation (WHO) for their consideration in the development of global guidance and present a narrative review on the management of anovulatory infertility in women with polycystic ovary syndrome (PCOS). OBJECTIVE AND RATIONALE: The aim of this paper was to present an evidence base for the management of anovulatory PCOS.

Author(s): 
Balen, Adam H.
Morley, Lara C.
Misso, Marie
Franks, Stephen
Legro, Richard S.
Wijeyaratne, Chandrika N.
Stener-Victorin, Elisabet
Fauser, Bart C. J. M.
Norman, Robert J.
Teede, Helena
Publication Title: 
Explore (New York, N.Y.)

RESEARCH QUESTION: Arthralgia affects postmenopausal breast cancer survivors (BCS) receiving aromatase inhibitors (AI), which may result in reduced function and long-term well-being. This is an exploratory, qualitative investigation of BCS who participated in a yoga-based program to understand impact on joint pain and various aspects of quality of life (QOL) through a yoga program.

Author(s): 
Galantino, Mary Lou
Greene, Laurie
Archetto, Benjamin
Baumgartner, Melissa
Hassall, Paula
Murphy, Joanna Kluz
Umstetter, Jamie
Desai, Krupali
Publication Title: 
Cancer Research

In breast cancer, in situ estrogen production has been demonstrated to play a major role in promoting tumor growth. Aromatase is the enzyme responsible for the conversion of androgen substrates into estrogens. This enzyme is highly expressed in breast cancer tissue compared with normal breast tissue. A wine extract fraction was recently isolated from red wine that exhibited a potent inhibitory action on aromatase activity.

Author(s): 
Eng, Elizabeth T.
Ye, JingJing
Williams, Dudley
Phung, Sheryl
Moore, Roger E.
Young, Mary K.
Gruntmanis, Ugis
Braunstein, Glenn
Chen, Shiuan
Publication Title: 
Cancer

BACKGROUND: Arthralgia is common in postmenopausal breast cancer survivors (BCS) who are receiving aromatase inhibitors (AIs). The objective of this study was to evaluate the perceived onset, characteristics, and risk factors for AI-related arthralgia (AIA). METHODS: In a cross-sectional survey of postmenopausal BCS who were receiving adjuvant AI therapy at a university-based oncology clinic, patient-reported attribution of AIs as a cause of joint pain was used as the primary outcome. Multivariate logistic regression analyses were performed to evaluate risk factors.

Author(s): 
Mao, Jun J.
Stricker, Carrie
Bruner, Deborah
Xie, Sharon
Bowman, Marjorie A.
Farrar, John T.
Greene, Brandon T.
DeMichele, Angela
Publication Title: 
Integrative Cancer Therapies

BACKGROUND: Arthralgia affects postmenopausal women receiving aromatase inhibitors (AIs) for breast cancer. Given the existing evidence for electroacupuncture (EA) for treatment of osteoarthritis in the general population, this study aims to establish the feasibility of studying EA for treating AI-related arthralgia. PATIENTS AND METHODS: Postmenopausal women with stage I-III breast cancer who reported AI-related arthralgia were enrolled in a single-arm feasibility trial. EA was provided twice a week for 2 weeks followed by 6 weekly treatments.

Author(s): 
Mao, James J.
Bruner, Deborah W.
Stricker, Carrie
Farrar, John T.
Xie, Sharon X.
Bowman, Marjorie A.
Pucci, Donna
Han, Xiaoyan
DeMichele, Angela
Publication Title: 
Breast Cancer Research and Treatment

Hot flashes in breast cancer survivors (BCS) receiving adjuvant aromatase inhibitor (AI) therapy are common, but risk factors for these symptoms are ill-defined. This study tested if body size is associated with hot flashes in BCS on AI therapy. A cross-sectional study of postmenopausal BCS receiving adjuvant AI therapy was performed. The primary outcome was occurrence of patient-reported hot flashes. The primary exposures of interest were current body size and weight change since breast cancer diagnosis.

Author(s): 
Su, H. Irene
Sammel, Mary D.
Springer, Erin
Freeman, Ellen W.
DeMichele, Angela
Mao, Jun J.

Pages

Subscribe to RSS - Aromatase Inhibitors